$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040475 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$17.69M	$16.02M	$15.32M
YoY Change	15.5%	22.85%	117.76%
Cost Of Revenue	$1.788M	$1.751M	$2.369M
YoY Change	-24.52%	-21.41%	202.66%
Gross Profit	$15.90M	$14.27M	$12.95M
YoY Change	22.82%	31.97%	107.13%
Gross Profit Margin	89.89%	89.07%	84.53%
Selling, General & Admin	$16.34M	$13.88M	$14.11M
YoY Change	15.78%	15.05%	54.02%
% of Gross Profit	102.73%	97.23%	108.98%
Research & Development	$651.5K	$986.5K	$1.034M
YoY Change	-36.99%	-7.06%	243.71%
% of Gross Profit	4.1%	6.91%	7.99%
Depreciation & Amortization	$1.095M	$116.6K	$814.3K
YoY Change	34.47%	9.64%	305.11%
% of Gross Profit	6.89%	0.82%	6.29%
Operating Expenses	$16.13M	$15.18M	$15.96M
YoY Change	1.06%	8.91%	65.15%
Operating Profit	-$226.0K	-$906.7K	-$3.012M
YoY Change	-92.5%	-70.96%	-11.75%
Interest Expense	-$36.45K	$188.3K	$0.00
YoY Change		71.66%	-100.0%
% of Operating Profit
Other Income/Expense, Net		-$188.3K	-$111.6K
YoY Change		71.66%
Pretax Income	-$262.4K	-$1.095M	-$4.163M
YoY Change	-93.7%	-66.12%	17.06%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$237.2K	-$1.060M	-$4.107M
YoY Change	-94.22%	-30.66%	15.75%
Net Earnings / Revenue	-1.34%	-6.62%	-26.82%
Basic Earnings Per Share		-$0.13
Diluted Earnings Per Share	-$0.03	-$0.13	-$0.51
COMMON SHARES
Basic Shares Outstanding	8.538M shares	8.522M shares	8.304M shares
Diluted Shares Outstanding		8.332M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.147M	$6.240M	$8.959M
YoY Change	-42.55%	-39.33%	-51.97%
Cash & Equivalents	$5.147M	$6.236M	$8.959M
Short-Term Investments
Other Short-Term Assets	$608.4K	$620.0K	$1.105M
YoY Change	-44.92%	-38.89%	20.42%
Inventory	$4.718M	$5.021M	$3.549M
Prepaid Expenses
Receivables	$8.533M	$7.500M	$6.806M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.01M	$19.38M	$20.62M
YoY Change	-7.81%	-5.82%	-16.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.258M	$1.327M	$1.416M
YoY Change	-11.19%	-9.76%	-13.09%
Goodwill	$3.602M	$3.602M	$3.602M
YoY Change	0.0%	9.89%
Intangibles	$44.93M	$45.99M	$31.51M
YoY Change	42.58%	42.75%	566.46%
Long-Term Investments	$3.084M	$3.080M	$3.084M
YoY Change	0.0%	-0.14%	-38.53%
Other Assets
YoY Change
Total Long-Term Assets	$54.87M	$56.10M	$40.42M
YoY Change	35.74%	37.15%	242.88%
TOTAL ASSETS
Total Short-Term Assets	$19.01M	$19.38M	$20.62M
Total Long-Term Assets	$54.87M	$56.10M	$40.42M
Total Assets	$73.87M	$75.47M	$61.04M
YoY Change	21.03%	22.77%	67.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.002M	$2.000M	$1.393M
YoY Change	43.74%	123.74%	217.86%
Accrued Expenses	$10.09M	$9.990M	$10.22M
YoY Change	-1.28%	20.61%	88.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$580.4K	$232.1K
YoY Change
Total Short-Term Liabilities	$13.77M	$13.23M	$12.81M
YoY Change	7.51%	43.68%	112.65%
LONG-TERM LIABILITIES
Long-Term Debt	$9.113M	$9.458M	$0.00
YoY Change
Other Long-Term Liabilities	$2.723M	$4.872M	$6.004M
YoY Change	-54.65%	-30.95%
Total Long-Term Liabilities	$15.52M	$18.15M	$6.509M
YoY Change	138.36%	138.08%	2830.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.77M	$13.23M	$12.81M
Total Long-Term Liabilities	$15.52M	$18.15M	$6.509M
Total Liabilities	$29.28M	$31.38M	$19.32M
YoY Change	51.61%	86.44%	209.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.04M	-$27.80M	-$23.39M
YoY Change	19.84%	45.43%	53.56%
Common Stock	$72.87M	$72.12M	$65.22M
YoY Change	11.72%	11.68%	42.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.83M	$44.32M	$41.83M
YoY Change
Total Liabilities & Shareholders Equity	$73.87M	$75.47M	$61.04M
YoY Change	21.03%	22.77%	67.7%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$237.2K	-$1.060M	-$4.107M
YoY Change	-94.22%	-30.66%	15.75%
Depreciation, Depletion And Amortization	$1.095M	$116.6K	$814.3K
YoY Change	34.47%	9.64%	305.11%
Cash From Operating Activities	-$845.6K	$1.060M	-$645.0K
YoY Change	31.09%	-164.51%	-63.85%
INVESTING ACTIVITIES
Capital Expenditures	$55.25K	$170.0K	$53.37K
YoY Change	3.52%	-88.2%	-137.66%
Acquisitions		$10.00M
YoY Change
Other Investing Activities	-$2.100K	-$9.940M	-$323.6K
YoY Change	-99.35%	353.6%	-76.03%
Cash From Investing Activities	-$57.35K	-$10.11M	-$376.9K
YoY Change	-84.79%	1247.26%	-74.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-188.9K	9.230M	-304.4K
YoY Change	-37.95%		-31.21%
NET CHANGE
Cash From Operating Activities	-845.6K	1.060M	-645.0K
Cash From Investing Activities	-57.35K	-10.11M	-376.9K
Cash From Financing Activities	-188.9K	9.230M	-304.4K
Net Change In Cash	-1.092M	180.0K	-1.326M
YoY Change	-17.69%	-107.52%	-64.33%
FREE CASH FLOW
Cash From Operating Activities	-$845.6K	$1.060M	-$645.0K
Capital Expenditures	$55.25K	$170.0K	$53.37K
Free Cash Flow	-$900.8K	$890.0K	-$698.4K
YoY Change	28.98%	-128.86%	-57.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000714256
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt		usd
CY2022Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	SMTI	Cash Payment Of Finance And Earnout Liabilities CashPaymentOfFinanceAndEarnoutLiabilities		usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	SMTI	Right Of Use Assets Obtained In Exchange For Lease Obligations RightOfUseAssetsObtainedInExchangeForLeaseObligations		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39678
	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
	dei	City Area Code CityAreaCode	(817)
	dei	Local Phone Number LocalPhoneNumber	529-2300
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SMTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8538489	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6235912	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8958995	usd
CY2023Q3	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2022Q4	SMTI	Royalty Receivable RoyaltyReceivable	99594	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5021030	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3549000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	621690	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1104611	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	19375303	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20616509	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1327056	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2094188	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	806402	usd
CY2023Q3	us-gaap	Goodwill Goodwill	3601781	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45991466	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31509980	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	56098769	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40418877	usd
CY2023Q3	us-gaap	Assets Assets	75474072	usd
CY2022Q4	us-gaap	Assets Assets	61035386	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3583439	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2144475	usd
CY2023Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6084654	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7758284	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1162880	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	322206	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313933	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	232143	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13227076	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12806309	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4871986	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6003811	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846293	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	505291	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9458254	usd
CY2023Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	1972673	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18149206	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6509102	usd
CY2023Q3	us-gaap	Liabilities Liabilities	31376282	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19315411	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8540226	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8540226	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8299957	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8299957	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8540	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8300	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72107881	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65213987	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27799621	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23394757	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	44316800	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41827530	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-219010	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-107555	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44097790	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75474072	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61035386	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16024948	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13044571	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47300029	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30526572	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1751349	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	2228561	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6064524	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3991728	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	14273599	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	10816010	usd
	us-gaap	Gross Profit GrossProfit	41235505	usd
	us-gaap	Gross Profit GrossProfit	26534844	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13877879	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12062195	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40658424	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31865958	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	986454	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1061387	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3480906	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2333024	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	997674	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	814881	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1556752	usd
CY2023Q3	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	681753	usd
CY2022Q3	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	-109689	usd
	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	1494910	usd
	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	-173116	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	15180254	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	14048152	usd
	us-gaap	Operating Expenses OperatingExpenses	45224663	usd
	us-gaap	Operating Expenses OperatingExpenses	35928850	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-906655	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3232142	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3989158	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9394006	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	188294	usd
	us-gaap	Interest Expense InterestExpense	188300	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188294	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188300	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-379633	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1094949	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3232142	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4177458	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9773639	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1702890	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1529252	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
	us-gaap	Profit Loss ProfitLoss	-3928843	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34579	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58792	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-111455	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-98485	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1060370	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1470460	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4066003	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3830358	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8332341	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8332341	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8107261	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8107261	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8244503	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8244503	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7836882	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7836882	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1623118	usd
CY2022Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-102931	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3156505	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28515686	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	703400	usd
CY2022Q2	SMTI	Stock Issued During Period Value Common Stock For Acquisitions StockIssuedDuringPeriodValueCommonStockForAcquisitions	5096444	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4612645	usd
CY2022Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	220000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	756914	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39465089	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	683202	usd
CY2022Q3	SMTI	Stock Issued During Period Value Issuance Of Common Stock For Acquisitions StockIssuedDuringPeriodValueIssuanceOfCommonStockForAcquisitions	6029429	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1529252	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44648468	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	597305	usd
CY2023Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-655942	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1033761	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1127332	usd
CY2023Q2	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	224576	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40964498	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40964498	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	857526	usd
CY2023Q3	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	281070	usd
CY2023Q3	SMTI	Stock Issued During Period Value Issuance Of Common Stock For Acquisitions StockIssuedDuringPeriodValueIssuanceOfCommonStockForAcquisitions	3089645	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44097790	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44097790	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
	us-gaap	Profit Loss ProfitLoss	-3928843	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1556752	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2876	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214061	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	220000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	222691	usd
	us-gaap	Inventory Write Down InventoryWriteDown	289406	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2582163	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1971537	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	243988	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	189409	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5844796	usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	39699	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2055	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	-0	usd
	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	1494910	usd
	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	-173116	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	794344	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	754934	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-87516	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-10920	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1664714	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	451838	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-482921	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69490	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	547186	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-800788	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	30711	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-126812	usd
	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	557295	usd
	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	947130	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1673629	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1516858	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-182498	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-189990	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2397024	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4909854	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210970	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93651	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	894	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	600000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	9942750	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2191919	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10153070	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3134676	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	9688341	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1033761	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-150296	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-102931	usd
	SMTI	Cash Payment Of Finance And Earnout Liabilities CashPaymentOfFinanceAndEarnoutLiabilities	744795	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	220000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9827011	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-322931	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2723083	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8367461	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6235912	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10285380	usd
	us-gaap	Interest Paid Net InterestPaidNet	146546	usd
	SMTI	Right Of Use Assets Obtained In Exchange For Lease Obligations RightOfUseAssetsObtainedInExchangeForLeaseObligations	1531773	usd
	us-gaap	Stock Issued1 StockIssued1	3089645	usd
	us-gaap	Stock Issued1 StockIssued1	15738518	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	3759642	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	6882151	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1803440	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zyaadI1BNCab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_827_zlIJoqkodaNj">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority-owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zDNVvKoQcSug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z7EqOmzcncB9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	159557	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	192215	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16024948	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13044571	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47300029	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30526572	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128061	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214061	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	220000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	511089	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	265089	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5297	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4761	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	152701	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	129689	usd
	us-gaap	Inventory Write Down InventoryWriteDown	222691	usd
	us-gaap	Inventory Write Down InventoryWriteDown	289406	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	327492	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	523832	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2399804	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2156422	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1072748	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	739986	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1327056	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023Q3	us-gaap	Depreciation Depreciation	116596	usd
CY2022Q3	us-gaap	Depreciation Depreciation	106347	usd
	us-gaap	Depreciation Depreciation	332762	usd
	us-gaap	Depreciation Depreciation	300655	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7166691	usd
	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Additions BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAdditions	893000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1494910	usd
	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Settlements BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements	-692795	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5871986	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000.0	usd
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	9750000	usd
CY2023Q2	SMTI	Asset Acquisition Consideration Transferred Equity Shares AssetAcquisitionConsiderationTransferredEquityShares	73809	shares
CY2023Q2	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Stock Closing Consideration AssetAcquisitionConsiderationTransferredFairValueOfStockClosingConsideration	3089645	usd
CY2023Q2	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Installment Payments AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments	2040808	usd
CY2023Q2	SMTI	Asset Acquisition Consideration Transferred Cash Paid For Inventory AssetAcquisitionConsiderationTransferredCashPaidForInventory	30007	usd
CY2023Q2	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Petito Services Defined Payments AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments	825834	usd
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	893000	usd
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	162743	usd
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	16792037	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y6M
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	881079	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	708534	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2247482	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1256097	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	974018	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3896070	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3896070	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3878815	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3764962	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3731721	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	25849810	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45991466	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q3	us-gaap	Investments Investments	3084278	usd
CY2022Q4	us-gaap	Investments Investments	3084278	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2094188	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2168499	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	295268	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	210317	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	264291	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	210897	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	116285	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	505017	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	532053	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	379529	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	297947	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	295689	usd
CY2023Q3	SMTI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	604049	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2730569	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	562070	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2168499	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	322206	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846293	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0759	pure
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q3	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	2055	usd
CY2022Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	0	usd
CY2023Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	59603	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	9690397	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	232143	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9458254	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	580357	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1625000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1950000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1950000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3644643	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q3	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	59603	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	0	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2055	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2055	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	50250	usd
	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	4020	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	us-gaap	Cash Cash	693000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	107797	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	4287777	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	857526	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	683202	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2582163	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1971537	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3980624	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	181102	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	118912	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	39.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	129342	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	22.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	11115	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	32.96
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	159557	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	34.27
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.65
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	50318	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.58
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	95873	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	95873	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2023Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2023Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P7Y
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1702890	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
smti-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-040475-index-headers.html	Edgar Link	pending
0001493152-23-040475-index.html	Edgar Link	pending
0001493152-23-040475.txt	Edgar Link	pending
0001493152-23-040475-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20230930.xsd	Edgar Link	pending
smti-20230930_def.xml	Edgar Link	unprocessable
smti-20230930_lab.xml	Edgar Link	unprocessable
smti-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2023 Q4 Form 10-Q Financial Statement

#000149315223040475 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2023 Q4 Form 10-Q Financial Statement

#000149315223040475 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti